Patents by Inventor John Adams Lowe

John Adams Lowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperidinyl pyrimidine amides as Kv7 potassium channel openers
    Patent number: 8883812
    Abstract: The present invention relates to compounds of Formula (I) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: November 11, 2014
    Assignee: Pfizer Inc.
    Inventors: Michelle Marie Claffey, Jennifer Elizabeth Davoren, John Adams Lowe, III, Robert Joseph Mather
  • Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers
    Publication number: 20130150391
    Abstract: The present invention relates to compounds of Formula (I) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.
    Type: Application
    Filed: June 20, 2011
    Publication date: June 13, 2013
    Applicant: PFIZER INC.
    Inventors: Michelle Marie Claffey, Jennifer Elizabeth Davoren, John Adams Lowe, III, Robert Joseph Mather
  • 2-aminopyridines containing fused ring substituents
    Patent number: 7012078
    Abstract: The present invention relates to 2-aminopyridine derivatives of the formula wherein G, R1 and R2 are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: March 14, 2006
    Assignee: Pfizer Inc.
    Inventor: John Adams Lowe, III
  • New pharmaceutical combinations for NOS inhibitors
    Publication number: 20040229911
    Abstract: The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.
    Type: Application
    Filed: June 14, 2004
    Publication date: November 18, 2004
    Applicant: Pfizer Inc
    Inventors: Mario David Saltarelli, John Adams Lowe
  • Difluoromethylene aromatic ethers as inhibitors of glycine transport
    Patent number: 6710071
    Abstract: This invention relates to a series of difluoromethylene aromatic ethers of the formula wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: March 23, 2004
    Assignee: Pfizer Inc
    Inventor: John Adams Lowe, III
  • Fluoroalkyoxybenzylamino derivatives of nitrogen containing heterocycles
    Publication number: 20030199540
    Abstract: The present invention relates to novel fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula 1
    Type: Application
    Filed: March 4, 2003
    Publication date: October 23, 2003
    Inventors: John Adams Lowe, Terry Jay Rosen
  • Urea derivatives useful as anticancer agents
    Publication number: 20030191279
    Abstract: The present invention relates to compounds of formula I 1
    Type: Application
    Filed: February 20, 2003
    Publication date: October 9, 2003
    Inventors: Steven Wayne Goldstein, John Adams Lowe, Kelly Porter Longo, Mohamed Mohamed Ali Awad, Chakrapani Subramanyam, Peter Hans Dorff
  • 2-Aminopyridines containing fused ring substituents
    Publication number: 20030149017
    Abstract: The present invention relates to 2-aminopyridine derivatives of the formula 1
    Type: Application
    Filed: December 6, 2002
    Publication date: August 7, 2003
    Applicant: Pfizer Inc.
    Inventor: John Adams Lowe
  • Difluoromethylene aromatic ethers as inhibitors of glycine transport
    Publication number: 20030045569
    Abstract: This invention relates to a series of difluoromethylene aromatic ethers of the formula 1
    Type: Application
    Filed: August 15, 2002
    Publication date: March 6, 2003
    Applicant: Pfizer Inc.
    Inventor: John Adams Lowe
  • Branched alkoxy-substituted 2-aminopyridines as NOS inhibitors
    Patent number: 6362195
    Abstract: The present invention relates to 6-phenyl-pyridin-2-ylamine derivatives of the formula wherein R1, R2, R3 and R4 are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: March 26, 2002
    Assignee: Pfizer Inc.
    Inventor: John Adams Lowe, III
  • Branched alkoxy-subsituted 2-aminopyridines
    Publication number: 20020022642
    Abstract: The present invention relates to 6-phenyl-pyridin-2-ylamine derivatives of the formula 1
    Type: Application
    Filed: September 20, 2001
    Publication date: February 21, 2002
    Inventor: John Adams Lowe
  • 2-aminopyridines containing fused ring substituents
    Publication number: 20010049379
    Abstract: The present invention relates to 2-aminopyridine derivatives of the formula 1
    Type: Application
    Filed: December 20, 2000
    Publication date: December 6, 2001
    Inventor: John Adams Lowe
  • Quinuclidine derivatives
    Patent number: 6222038
    Abstract: Compounds of the formula wherein R1 is methoxy and R2 is selected from the group consisting of methyl, ethyl, isopropyl, sec-butyl and tert-butyl; and the pharmaceutically acceptable salts of such compounds. These compounds are substance P antagonists and useful in the treatment of gastrointestinal disorders, inflammatory disorders, central nervous system disorders and pain.
    Type: Grant
    Filed: January 24, 1995
    Date of Patent: April 24, 2001
    Inventors: Fumitaka Ito, Hiroshi Kondo, Masami Nakane, John Adams Lowe, III, Terry Jay Rosen, Kaoru Shimada
  • Quinuclidine derivatives
    Patent number: 5939433
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is methoxy and R.sup.2 is selected from the group consisting of methyl, ethyl, isopropyl, sec-butyl and tert-butyl; and the pharmaceutically acceptable salts of such compounds.These compounds are substance P antagonists and useful in the treatment of gastrointestinal disorders, inflammatory disorders, central nervous system disorders and pain.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: August 17, 1999
    Assignee: Pfizer Inc
    Inventors: Fumitaka Ito, Hiroshi Kondo, Masami Nakane, Kaoru Shimada, John Adams Lowe, III, Terry Jay Rosen
  • Quinuclidine derivatives
    Patent number: 5854256
    Abstract: Quinuclidine derivatives of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein m, P, Z, Y, R.sup.1, R.sup.2 and R.sup.3 are as defined below. The compounds are substance P antagonists and, therefore, are useful in treating gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: December 29, 1998
    Assignee: Pfizer Inc.
    Inventor: John Adams Lowe, III
  • Quinuclidine derivatives
    Patent number: 5821248
    Abstract: Quinuclidine derivatives of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein m, P, Z, Y, R.sup.1, R.sup.2 and R.sup.3 are as defined below. The compounds are substance P antagonists and, therefore, are useful in treating gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: October 13, 1998
    Assignee: Pfizer Inc.
    Inventor: John Adams Lowe, III
  • Quinuclidine derivatives
    Patent number: 5807867
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is methoxy and R.sup.2 is selected from the group consisting of methyl, ethyl, isopropyl, sec-butyl and tert-butyl; and the pharmaceutically acceptable salts of such compounds.These compounds are substance P antagonists and useful in the treatment of gastrointestinal disorders, inflammatory disorders, central nervous system disorders and pain.
    Type: Grant
    Filed: May 23, 1994
    Date of Patent: September 15, 1998
    Assignee: Pfizer Inc.
    Inventors: Fumitaka Ito, Hiroshi Kondo, Masami Nakane, Kaoru Shimada, John Adams Lowe, III, Terry Jay Rosen
  • Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
    Patent number: 5773450
    Abstract: The present invention relates to novel fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula ##STR1## wherein Q, X.sup.1, x.sup.2 and X.sup.3 are as defined below. These novel compounds are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
    Type: Grant
    Filed: December 14, 1993
    Date of Patent: June 30, 1998
    Assignee: Pfizer Inc.
    Inventors: John Adams Lowe, III, Terry Jay Rosen
  • Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
    Patent number: 5744480
    Abstract: The present invention relates to novel fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula ##STR1## wherein Q, X.sup.1, X.sup.2 and X.sup.3 are as defined below. These novel compounds are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: April 28, 1998
    Assignee: Pfizer Inc.
    Inventors: John Adams Lowe, III, Terry Jay Rosen
  • Quinuclidine derivatives
    Patent number: 5698568
    Abstract: Quinuclidine derivatives of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein m, P, Z, Y, R.sup.1, R.sup.2 and R.sup.3 are as defined below. The compounds are substance P antagonists and, therefore, are useful in treating gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: December 16, 1997
    Assignee: Pfizer Inc.
    Inventor: John Adams Lowe, III